Clinical trial
A Phase II Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Treated With Gemcitabine Followed by Brentuximab Vedotin Maintenance
NCT03496779 is registered in ClinicalTrials.gov with The Lymphoma Academic Research Organisation as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Treated With Gemcitabine Followed by Brentuximab Vedotin Maintenance
- Lead sponsor
- The Lymphoma Academic Research Organisation
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- April 10, 2018
- Completion date
- October 8, 2022
- Enrollment
- 71 (actual)
- Sites
- 39
Conditions
As the registry lists them; a condition with its own page is linked.
refractory peripheral t-cell lymphoma, relapsed peripheral t-cell lymphoma